Phase I Clinical Study of MK-0683 in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)

Trial Profile

Phase I Clinical Study of MK-0683 in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2014

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 03 Jul 2012 Actual end date changed from Jun 2011 to Jul 2011 as reported by ClinicalTrials.gov.
    • 03 Jul 2012 Actual patient number is 10 according to ClinicalTrials.gov.
    • 11 Aug 2011 Actual end date changed from Sep 2011 to Jun 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top